Immunic, Inc.
NASDAQ:IMUX
1.18 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.006 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.111 | 0.077 | 0.085 | 0.039 | 0.05 | 0.015 | 0.998 | 1.808 | 1.328 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.111 | -0.077 | -0.085 | -0.039 | -0.05 | -0.015 | -0.998 | -1.802 | -1.328 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | -285.297 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 83.215 | 71.255 | 61.115 | 38.637 | 22.512 | 24.825 | 39.341 | 30.046 | 39.773 | 39.479 | 21.787 | 5.097 | 5.515 |
| General & Administrative Expenses
| 16.008 | 15.263 | 13.3 | 10.334 | 14.52 | 13.585 | 13.314 | 11.22 | 12.347 | 10.863 | 9.615 | 0 | 0 |
| Selling & Marketing Expenses
| -0.111 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 16.008 | 15.263 | 13.3 | 10.334 | 14.52 | 13.585 | 13.314 | 11.22 | 12.347 | 10.863 | 9.615 | 4.483 | 3.066 |
| Other Expenses
| 0 | -1.96 | 17.25 | 4.896 | 1.992 | 0.028 | 0 | 0.297 | 0.097 | 2.675 | 0 | 0 | 0 |
| Operating Expenses
| 99.223 | 86.518 | 91.665 | 48.971 | 37.032 | 38.41 | 52.655 | 41.266 | 52.12 | 50.342 | 31.402 | 9.58 | 8.581 |
| Operating Income
| -99.223 | -119.488 | -91.665 | -48.971 | -37.032 | -42.024 | -52.655 | -41.266 | -52.12 | -50.342 | -31.402 | -9.58 | -8.581 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | -6,534.476 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 5.611 | -0.919 | -1.28 | 4.954 | 2.099 | -3.586 | -0.073 | 0.297 | 0.097 | 2.675 | -1.321 | 3.288 | 11.949 |
| Income Before Tax
| -93.612 | -120.407 | -92.945 | -44.017 | -34.933 | -41.475 | -52.078 | -40.969 | -52.023 | -47.667 | -32.718 | -6.701 | -5.879 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | -6,487.446 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 33.889 | -0.151 | -0.058 | -0.107 | 0.549 | -0.577 | -1.808 | -1.328 | -1.087 | 0 | 0.413 | 9.249 |
| Net Income
| -93.612 | -154.296 | -92.794 | -43.959 | -34.826 | -41.475 | -52.078 | -40.969 | -52.023 | -47.667 | -32.718 | -6.701 | -5.879 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | -6,487.446 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -2.11 | -4.85 | -3.92 | -2.81 | -4.51 | -39.16 | -52.26 | -52.21 | -82.73 | -118.76 | -2,319.77 | -475.11 | -416.83 |
| EPS Diluted
| -2.11 | -4.85 | -3.92 | -2.81 | -4.51 | -39.16 | -52.26 | -52.21 | -82.73 | -118.76 | -2,319.77 | -475.11 | -416.83 |
| EBITDA
| -99.112 | -53.548 | -91.665 | -48.932 | -36.982 | -34.069 | -51.584 | -41.266 | -52.12 | -50.342 | -30.598 | -8.925 | -7.618 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | -6,534.476 | 0 | 0 | 0 | 0 | 0 |